In Brief: Aleve
This article was originally published in The Tan Sheet
Executive Summary
Aleve: Phase IV clinical study on efficacy of the OTC naproxen sodium analgesic for headache has been accepted by FDA. The Procter-Syntex product was approved by FDA with the general analgesic indications, including headache, in January 1994 with the understanding that the firm would conduct postmarket studies to comply with future agency changes to OTC analgesic requirements. In January 1995, FDA announced that separate studies for headache, dysmenorrhea and fever would be required before analgesics could make those claims ("The Tan Sheet" Jan. 16, p. 1). The changes grew out of the Aleve advisory committee review in June 1993 ("The Tan Sheet" June 7, 1993, p. 5). Separately, P&G introduced Aleve in the Puerto Rican market July 18..
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning